The first prototype of spot-scanning proton arc treatment delivery
The first prototype of spot-scanning proton arc treatment delivery
复制标题
DOI：
10.1016/j.radonc.2019.04.032
复制
发表时间：
2019-08-01
影响因子：
5.7
通讯作者：
Ding, Xuanfeng
中科院分区：
文献类型：
--
作者：
Li, Xiaoqiang;Liu, Gang;Ding, Xuanfeng
目的：我们报告了临床质子束治疗机上的第一个点扫描弧形治疗（SPArc）输送原型，并评估其输送准确性和效率。方法和材料：开发了一种名为质子动态弧形输送（PDAD）的新模块，可以在旋转IBA Proteus（R）One质子机上的机架的同时同时输送点扫描质子束治疗。进行了一系列的测量，以验证基本的光束特性。随后，进行了脑部SPArc计划的患者特定质量保证（QA）。还记录了总SPArc治疗输送时间，并与临床输送的调强质子治疗（IMPT）治疗时间进行比较。最后，SPArc计划的日志文件进行了分析和处理，以重建实际交付dose.Results：所有的基本射束特性被确认在PDAD模式，类似于使用固定机架交付在临床模式下测量。具有相似或上级计划质量的脑SPArc计划在4分钟内交付，而三视野IMPT计划的临床治疗总共需要11分钟。患者QA结果显示，测量和计算的剂量分布之间具有良好的一致性，伽马指数为98.6%（3%/3 mm）。日志文件的分析证实了SPArc计划交付的准确性，重建和计划doses.Conclusion之间的伽玛指数为98.3%（1%/1 mm）的第一个原型的动态质子弧输送的临床质子治疗系统成功地进行。测量和模拟证明了SPArc治疗在临床要求范围内的可行性。(C)2019爱思唯尔B. V.保留所有权利。
Purpose: We report the first prototype of spot-scanning arc treatment (SPArc) delivery on a clinical proton beam therapy machine and evaluate its delivery accuracy and efficiency.Methods and materials: A new module called Proton Dynamic Arc Delivery (PDAD) was developed to allow simultaneously delivering spot-scanning proton beam treatments while rotating the gantry on an IBA Proteus (R) One proton machine. A series of measurements was performed to validate the basic beam characteristics. Subsequently, patient specific quality assurance (QA) of a brain SPArc plan was performed. Total SPArc treatment delivery time was also recorded and compared to the clinically delivered intensity modulated proton therapy (IMPT) treatment time. Finally, the log file of the SPArc plan was analyzed and processed to reconstruct the actual delivered dose.Results: All the basic beam characteristics were confirmed in the PDAD mode, similar as those measured using fixed gantry deliveries in clinical mode. The brain SPArc plan with similar or superior plan quality was delivered in 4 mins compared to total 11 mins for the clinical treatment of the three-field IMPT plan. The patient QA result showed a good agreement between the measured and calculated dose distributions with the gamma index of 98.6% (3%/3 mm). The analysis of the log file confirmed the accuracy of the SPArc plan delivery, with the gamma index of 98.3% (1%/1 mm) between reconstructed and the planned doses.Conclusion: The first prototype of dynamic proton arc delivery on a clinical proton therapy system was successfully performed. The measurements and simulations demonstrated the feasibility of SPArc treatment within the clinical requirements. (C) 2019 Elsevier B.V. All rights reserved.